Anti-cancer activity of anti-GLUT1 antibody-targeted polymeric micelles co-loaded with curcumin and doxorubicin

References

• Samanta AK, Huang HJ, Bast RC, Jr., Liao WS. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. J Biol Chem 2004;279:7576–83
   PubMed Web of Science ®Google Scholar
• Shostak K, Chariot A. NF-κB, stem cells and breast cancer: the links get stronger. Breast Cancer Res 2011;13:214
   PubMed Web of Science ®Google Scholar
• Voboril R, Weberova-Voborilova J. Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma 2006;53:518–23
   PubMed Web of Science ®Google Scholar
• Arlt A, Gehrz A, Muerkoster S, et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003;22:3243–51
   PubMed Web of Science ®Google Scholar
• Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochimica et Biophysica Acta (BBA) – Gene Regul Mech 2010;1799:775–87
   PubMed Web of Science ®Google Scholar
• Huang S, DeGuzman A, Bucana CD, Fidler IJ. Nuclear factor-kappaB activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 2000;6:2573–81
   PubMed Web of Science ®Google Scholar
• Yeh PY, Chuang S-E, Yeh K-H, et al. Involvement of nuclear transcription factor-κB in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells. Biochem Pharmacol 2003;66:25–33
   PubMed Web of Science ®Google Scholar
• Anand P, Sundaram C, Jhurani S, et al. Curcumin and cancer: an “old-age” disease with an “age-old” solution. Cancer Lett 2008;267:133–64
   PubMed Web of Science ®Google Scholar
• Chaturvedi MM, Sung B, Yadav VR, et al. NF-kappaB addiction and its role in cancer: ‘one size does not fit all'. Oncogene 2011;30:1615–30
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Schaffer M, Vizel B, et al. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010;62:1137–41
   PubMed Web of Science ®Google Scholar
• Tsai Y-M, Jan W-C, Chien C-F, et al. Optimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. Food Chem 2011;127:918–25
   PubMed Web of Science ®Google Scholar
• Shaikh J, Ankola DD, Beniwal V, et al. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009;37:223–30
   PubMed Web of Science ®Google Scholar
• Sun J, Bi C, Chan HM, et al. Curcumin-loaded solid lipid nanoparticles have prolonged in vitro antitumour activity, cellular uptake and improved in vivo bioavailability. Colloids Surf B: Biointerfaces 2013;111:367–75
   PubMed Web of Science ®Google Scholar
• Kakkar V, Muppu SK, Chopra K, Kaur IP. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm 2013 . [Epub ahead of print]. http://dx.doi.org/10.1016/j.ejpb.2013.02.005
   PubMed Web of Science ®Google Scholar
• Gangwar RK, Dhumale VA, Kumari D, et al. Conjugation of curcumin with PVP capped gold nanoparticles for improving bioavailability. Mat Sci Eng: C 2012;32:2659–63
   Web of Science ®Google Scholar
• Akhtar F, Rizvi MMA, Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv 2012;30:310–20
   PubMed Web of Science ®Google Scholar
• Sahu A, Bora U, Kasoju N, Goswami P. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)–palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 2008;4:1752–61
   PubMed Web of Science ®Google Scholar
• Suwannateep N, Banlunara W, Wanichwecharungruang SP, et al. Mucoadhesive curcumin nanospheres: biological activity, adhesion to stomach mucosa and release of curcumin into the circulation. J Control Release 2011;151:176–82
   PubMed Web of Science ®Google Scholar
• Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732–40
   PubMed Web of Science ®Google Scholar
• Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med 2013;34:121–38
   PubMed Web of Science ®Google Scholar
• Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654–62
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Seino Y, Fukumoto H, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990;170:223–30
   PubMed Web of Science ®Google Scholar
• Boado RJ, Black KL, Pardridge WM. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Mol Brain Res 1994;27:51–7
   PubMedGoogle Scholar
• Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993;72:2979–85
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–33
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011;11:85–95
   PubMed Web of Science ®Google Scholar
• Gu J, Yamamoto H, Fukunaga H, et al. Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer. Dig Dis Sci 2006;51:2198–205
   PubMed Web of Science ®Google Scholar
• Squires MS, Feltell RE, Wallis NG, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther 2009;8:324–32
   PubMed Web of Science ®Google Scholar
• Evans A, Bates V, Troy H, et al. Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. Cancer Chemother Pharmacol 2008;61:377–93
   PubMed Web of Science ®Google Scholar
• Szablewski L. Expression of glucose transporters in cancers. Biochimica et Biophysica Acta (BBA) - Rev Cancer 2013;1835:164–9
   PubMed Web of Science ®Google Scholar
• Cantuaria G, Magalhaes A, Penalver M, et al. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol 2000;79:33–7
   PubMed Web of Science ®Google Scholar
• Sung JY, Kim GY, Lim SJ, et al. Expression of the GLUT1 glucose transporter and p53 in carcinomas of the pancreatobiliary tract. Pathol Res Pract 2010;206:24–9
   PubMed Web of Science ®Google Scholar
• Firth JD. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct Cis-acting sequences. J Biol Chem 1995;270:29083–9
   PubMed Web of Science ®Google Scholar
• Airley R, Evans A, Mobasheri A, Hewitt SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: study using tissue microarrays. Ann Anat 2010;192:133–8
   PubMed Web of Science ®Google Scholar